Drugs / SAMARIUM LEXIDRONAM PENTASODIUM

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) QUADRAMET 1997-03-28 fda.gov

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00478075 Background Sep 2005 → Nov 2007 plasma cell myeloma Mayo Clinic Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as SAMARIUM LEXIDRONAM PENTASODIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561
Known as CYT-424 ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561
Known as Quadramet ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561
Known as Samarium (153 sm) lexidronam pentasodium ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561
Known as Samarium (153sm) lexidronam ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561
Known as Samarium (153sm) lexidronam sodium ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561
Known as samarium Sm 153 lexidronam pentasodium “Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to cancer cells and not harm normal cells.” NCT00478075
Known as Samarium sm 153 lexidronam pentasodium salt ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561
Known as Sm-153 edtmp pentasodium ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561
Modality Small molecule CHEMBL2110561
Route Intravenous “Patients receive samarium Sm 153 lexidronam pentasodium IV over 1 minute on day 1” NCT00478075